c-Met is a promising molecular target in oncological treatment, and related targeted therapy drugs have achieved inspiring results in clinical practice.
However, the clinical emergence of acquired resistance to c-Met inhibitors in recent years presents a significant therapeutic challenge.
In this study, we identified a novel
